rs2271338
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A three-variant ADHD risk haplotype in evolutionary conserved region 47, formed by rs17226398, rs56038622, and rs2271338, reduced enhancer activity by 40% in neuroblastoma and astrocytoma cells (p<sub>Bonferroni</sub> < .0001).
|
27692237 |
2016 |
rs5050
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Angiotensinogen rs5050 germline genetic variant as potential biomarker of poor prognosis in astrocytoma.
|
30383794 |
2018 |
rs17522122
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Whereas, rs4261436 (HR = 0.70, p = 0.045) and rs17522122 (HR = 0.75, p = 0.016) were associated with better prognosis of astrocytoma.
|
31759389 |
2019 |
rs4261436
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Whereas, rs4261436 (HR = 0.70, p = 0.045) and rs17522122 (HR = 0.75, p = 0.016) were associated with better prognosis of astrocytoma.
|
31759389 |
2019 |
rs1801516
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We propose the three-hit hypothesis as a triangle initiators includes D1853N as a first predisposing hit, IVS 38- 63T --> A as a second hit deriving from the first somatic evolution before differentiation and IVS 38- 30 A --> G as a third hit through the development of an astrocytoma.
|
18465141 |
2008 |
rs113488022
|
|
|
0.080 |
GeneticVariation |
BEFREE |
BRAF(V600E) mutation seems to define a subset of malignant astrocytomas in children, in which there is frequent concomitant homozygous deletion of CDKN2A (five of seven cases).
|
20068183 |
2010 |
rs113488022
|
|
|
0.080 |
GeneticVariation |
BEFREE |
BRAF V600E mutation was observed both in epithelioid tumor cells and in diffusely infiltrating less atypical astrocytoma cells.
|
24354918 |
2014 |
rs113488022
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Thus BRAF V600E mutation is common in desmoplastic non-infantile astrocytoma/ganglioglioma, but does not affect the prognosis.
|
29902580 |
2018 |
rs113488022
|
|
|
0.080 |
GeneticVariation |
BEFREE |
The BRAF(V600E) inhibitor PLX4720 significantly increased survival of mice after intracranial transplant of genetically relevant murine or human astrocytoma cells.
|
22586120 |
2012 |
rs113488022
|
|
|
0.080 |
GeneticVariation |
BEFREE |
An institutional cohort of 105 brain tumors (51 dysembryoplastic neuroepithelial tumors (DNTs), 14 subependymal giant cell astrocytomas (SEGAs), 12 glioblastoma with neuronal marker expression (GBM-N), and 28 pleomorphic xanthoastrocytomas (PXAs)) from 100 patients were investigated for the presence of BRAF(V600E) by direct sequencing.
|
25346165 |
2015 |
rs113488022
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Similar to previously reported findings on E-GBM associated with low-grade glioma, this case suggested that low-grade astrocytic glioma with BRAF V600E mutation progressed to E-GBM.
|
26602910 |
2016 |
rs113488022
|
|
|
0.080 |
GeneticVariation |
BEFREE |
With regard to implications for therapy, our results support evaluation of BRAF(V600E)-specific inhibitors for treating BRAF(V600E) MA patients.
|
22038996 |
2011 |
rs113488022
|
|
|
0.080 |
GeneticVariation |
BEFREE |
In summary, high grade astrocytomas with BRAF V600E, ATRX, and CDKN2A/B alternations had unique clinicopathological features and may be a novel subset of high grade glioma.
|
30972500 |
2019 |
rs121913377
|
|
|
0.080 |
GeneticVariation |
BEFREE |
In summary, high grade astrocytomas with BRAF V600E, ATRX, and CDKN2A/B alternations had unique clinicopathological features and may be a novel subset of high grade glioma.
|
30972500 |
2019 |
rs121913377
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Similar to previously reported findings on E-GBM associated with low-grade glioma, this case suggested that low-grade astrocytic glioma with BRAF V600E mutation progressed to E-GBM.
|
26602910 |
2016 |
rs121913377
|
|
|
0.080 |
GeneticVariation |
BEFREE |
An institutional cohort of 105 brain tumors (51 dysembryoplastic neuroepithelial tumors (DNTs), 14 subependymal giant cell astrocytomas (SEGAs), 12 glioblastoma with neuronal marker expression (GBM-N), and 28 pleomorphic xanthoastrocytomas (PXAs)) from 100 patients were investigated for the presence of BRAF(V600E) by direct sequencing.
|
25346165 |
2015 |
rs121913377
|
|
|
0.080 |
GeneticVariation |
BEFREE |
BRAF(V600E) mutation seems to define a subset of malignant astrocytomas in children, in which there is frequent concomitant homozygous deletion of CDKN2A (five of seven cases).
|
20068183 |
2010 |
rs121913377
|
|
|
0.080 |
GeneticVariation |
BEFREE |
The BRAF(V600E) inhibitor PLX4720 significantly increased survival of mice after intracranial transplant of genetically relevant murine or human astrocytoma cells.
|
22586120 |
2012 |
rs121913377
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Thus BRAF V600E mutation is common in desmoplastic non-infantile astrocytoma/ganglioglioma, but does not affect the prognosis.
|
29902580 |
2018 |
rs121913377
|
|
|
0.080 |
GeneticVariation |
BEFREE |
BRAF V600E mutation was observed both in epithelioid tumor cells and in diffusely infiltrating less atypical astrocytoma cells.
|
24354918 |
2014 |
rs121913377
|
|
|
0.080 |
GeneticVariation |
BEFREE |
With regard to implications for therapy, our results support evaluation of BRAF(V600E)-specific inhibitors for treating BRAF(V600E) MA patients.
|
22038996 |
2011 |
rs137852972
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In this study, we show that expression of seipin N-glycosylation mutant N88S led to decreased triglyceride (TG) content in astrocytoma and motor neuron cell lines.
|
23250914 |
2013 |
rs773442580
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In this study, we investigated whether stable expression of an activated Ki-Ras oncogenic mutant (G12V) in human astrocytoma cells leads to constitutive activation of the MAP kinase pathway and how this may influence cellular proliferation and signaling by epidermal growth factor (EGF) receptor.
|
9863009 |
1999 |
rs1057519897
|
|
G |
0.700 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs1057519898
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |